| Probiodrug–SEVERAL: investment, 201904 private placement €8.2m with 4.1m new shares at €2m led by Claus Christiansen et al. |
2019-04-09 |
| Phenex–Helmholtz: drug research, 201904– collab joint research in NASH + liver cancer metabolism with Heikenwälder Group at DKFZ |
2019-04-05 |
| AgomAb Therapeutics–Advent France Biotechnology: investment, 201904 financing round Series A totalling €21m incl co-lead investor Advent France |
2019-04-03 |
| AgomAb Therapeutics–Argenx: therapeutic antibodies, 201904– license excl to HGF-mimetic SIMPLE Antibodies developed in partnership |
2019-04-03 |
| AgomAb Therapeutics–Boehringer: investment, 201904 financing round Series A totalling €21m incl co-investor BIVF |
2019-04-03 |
| AgomAb Therapeutics–Instinctif Partners: public relations, 201901 service existent by Instinctif für UK + RoW |
2019-04-03 |
| AgomAb Therapeutics–Omnes Capital: investment, 201904 financing round Series A totalling €21m incl co-investor Omnes |
2019-04-03 |
| AgomAb Therapeutics–Pontifax: investment, 201904 financing round Series A totalling €21m incl co-investor Pontifax |
2019-04-03 |
| AgomAb Therapeutics–SEVERAL: investment, 201904 financing round Series A €21m co-led by V-Bio Ventures + Advent France Biotechnology |
2019-04-03 |
| AgomAb Therapeutics–V-Bio Ventures: investment, 201904 financing round Series A totalling €21m incl co-lead investor V-Bio Ventures |
2019-04-03 |
| Dyne Therapeutics–Atlas Venture: investment, 201904 financing round Series A totalling $50m incl founding investor Atlas Venture |
2019-04-03 |
| Dyne Therapeutics–Forbion: investment, 201904 financing round Series A totalling $50m incl co-investor Forbion |
2019-04-03 |
| Dyne Therapeutics–MPM Capital: investment, 201904 financing round Series A totalling $50m incl co-investor MPM Capital |
2019-04-03 |
| Dyne Therapeutics–SEVERAL: investment, 201904 financing round Series A $50m from founding investor Atlas Venture plus Forbion + MPM Capital |
2019-04-03 |
| LabCorp–Qiagen: molecular companion diagnostics, 201904– collab LabCorp joins Qiagen’s Day-One Lab Readiness program |
2019-04-03 |
| Rave LLC–Bruker Corp: investment, 201904 acquisition €na by Bruker |
2019-04-03 |
| Khloris Biosciences–Bayer: investment, 201904 seed financing €na from Leaps by Bayer |
2019-04-02 |
| Cambridge Innovation Capital–SEVERAL: investment, 201904 financing round £150m with Univ Cambridge as cornerstone investor |
2019-04-01 |
| Cambridge Innovation Capital–Univ Cambridge: investment, 201904 financing round totalling £150m incl cornerstone investor Univ Cambridge |
2019-04-01 |
| IFM Therapeutics–Novartis: investment, 201904– acquisition 100% of IMF Tre for upfront payment + milestones ANNOUNCED |
2019-04-01 |
| Karuna–Alexandria Real Estate: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Alexandria Venture Investments |
2019-04-01 |
| Karuna–ARCH Venture: investment, 201903–201904 financing round Series B totalling $80m incl exisiting + lead investor ARCH Venture Partners |
2019-04-01 |
| Karuna–Eventide Asset Management: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Eventide |
2019-04-01 |
| Karuna–Fidelity: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Fidelity Management & Research |
2019-04-01 |
| Karuna–Nan Fung: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Pivotal BioVenture Partners |
2019-04-01 |
| Karuna–Partner Fund Management: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Partner Fund Management |
2019-04-01 |
| Karuna–PureTech Health: investment, 201903–201904 financing round Series B totalling $80m incl exisiting investor PureTech Health |
2019-04-01 |
| Karuna–Sands Capital: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Sands Capital |
2019-04-01 |
| Karuna–SEVERAL: investment, 201903–201904 financing round Series B $80m led by ARCH Venture Partners incl $5m debt conversion |
2019-04-01 |
| Karuna–Sofinnova: investment, 201903–201904 financing round Series B totalling $80m incl $12m from new investor Sofinnova Investments |
2019-04-01 |
| Karuna–Wellcome Trust: investment, 201903–201904 financing round Series B totalling $80m incl exisiting investor Wellcome Trust |
2019-04-01 |
| Mogrify–United Kingdom (govt): grant, 201904 SBRI Healthcare funding for developm of cell therapy for osteoarthritis |
2019-04-01 |
| Bayer–ProteoNic: rec protein production technology, 201903– license non-excl €na to use 2G UNic technology to boost rec protein production |
2019-03-28 |
| Cellnovo–NONE: investment, 201903 in administration |
2019-03-28 |
| Inivata–Consilium: public relations, 201903 service existent by CSC |
2019-03-28 |
| Inivata–LifeSci: public relations, 201903 service existent IR by LifeSci Advisors |
2019-03-28 |
| Polyneuron–New Enterprise Associates: investment, 201903 financing round Series A totalling CHF22.5m incl new + co-lead investor NEA |
2019-03-28 |
| Polyneuron–SEVERAL: investment, 201903 financing round Series A CHF22.5m led by Sofinnova Partners + incl NEA |
2019-03-28 |
| Polyneuron–Sofinnova: investment, 201903 financing round Series A totalling CHF22.5m incl new + lead investor Sofinnova Partners |
2019-03-28 |
| Selvita–Trout Group: public relations, 201903 service existent media relations + IR by The Trout Group |
2019-03-28 |
| Univ College London–ArcherDx: PCR technology, 201903– collab €na use of AMP technology in UCL-sponsored UK lung cancer diagnostics TRACERx study |
2019-03-28 |
| H4Orphan Pharma–Cerenis: investment, 201903– excl negotations for potential merger w Cerenis owning 59% of combined company |
2019-03-27 |
| Cytena–High-Tech Gründerfonds: investment, 201903 financing round Series A totalling €3.m incl HTGF + two private investors |
2019-03-26 |
| Cytena–SEVERAL: investment, 201903 financing round Series A €3.m from HTGF + two private investors |
2019-03-26 |
| Evotec–Mark Foundation: investment, 201903–202102 research funding for two years €na by Mark Foundation with potential financial returns |
2019-03-26 |
| Lundbeck–Enamine: chemical compound libraries, 201903– supply expansion discovery chemistry services by Enamine |
2019-03-26 |
| Menarini–Curetis: molecular diagnostics, 201903– distribution excl long-term of Unyvero platform + cartridges in Europe by Menarini Diagnostics |
2019-03-26 |
| Synerkine Pharma–SEVERAL: investment, 201903 financing round Series A €3.3m from Thuja Capital + private investor + company founders |
2019-03-25 |
| Synerkine Pharma–Thuja Capital: investment, 201903 financing round Series A totalling €3.3m incl Thuja Capital + private investor + company founders |
2019-03-25 |
| Brammer Bio–Thermo Fisher: investment, 201903– acquisition $1.7b in cash from Ampersand Capital Partners + Founders ANNOUNCED |
2019-03-24 |
| Hookipa–SEVERAL: investment, 201903– IPO up to $86.3m at Nasdaq FILED |
2019-03-22 |
| Pierre Fabre–Institut Curie: cancer immunotherapy, 201903– collab extension I-O drug target discovery with IRPF |
2019-03-21 |
| United Kingdom (govt)–Cambridge Cancer Genomics: personalised immuno-oncology, 201903– collab long-term of Genomics England + CCG.ai |
2019-03-21 |
| Verona Pharma–ICR: public relations, 201903 service existent by ICR in US |
2019-03-21 |
| Verona Pharma–Novo Group: investment, 201903 existent investment Novo Holdings owns 11.76% shareholding in Verona Pharma plc |
2019-03-21 |
| Atlatl–Miltenyi Biotec: CliniMACSProdigy platform, 201903– collab co-founding of Atlatl-Macs Center for Gene + Cell Therapy in Shanghai |
2019-03-20 |
| NeoPhore–Optimum Strategic Communications: public relations, 201903 service existent by Optimum |
2019-03-20 |
| Pfizer–Vivet Therapeutics: VTX-801, collab developm €45m (incl acqu 15% share) + €560m milestones (incl acquisition of Vivet) |
2019-03-20 |
| Vivet Therapeutics–Pfizer: investment, 201903 acquisition 15% equity interest plus excl option to acquire all outstanding shares |
2019-03-20 |
| Oncimmune–Consilium: public relations, 201903 service existent by CSC |
2019-03-19 |
| Oncimmune–Qiagen: investment, 201903 up to 1.34% shareholding for Qiagen after Oncimmune’s acquisition of Protagen |
2019-03-19 |
| Protagen–Oncimmune: investment, 201903 acquisition of Portagen for up to £4.11m in up to 2.636m ordinary shares |
2019-03-19 |
| Mogrify–United Kingdom (govt): grant, 201903 Innovate UK funding £420k to use big data analysis to advance cell therapies |
2019-03-18 |
| Arxspan–Bruker Corp: investment, 201903 acquisition €na of Arxspan LLC by Bruker Corp |
2019-03-14 |
| Rocket Pharmaceuticals–MolMed: gene therapy, 201903– collab expansion developm + manufacture of lentiviral vectos by MolMed for three new indications |
2019-03-13 |
| Biogen–Fujifilm: biologics contract manfuacturing, 201903– supply manufacturing of biologicals for Biogen incl Tysabri |
2019-03-12 |
| Biogen–Fujifilm: investment, 201903– acquisition up to $890m in cash of Biogen’s Biologics Manufacturing Site in Hillerød Denmark |
2019-03-12 |
| Oxford BioMedica–Microsoft: bioinformatics, 201903–202102 collab r+d using MS Azure cloud + machine learing to optimise gene therapy vectors |
2019-03-12 |
| AstraZeneca–Seres Therapeutics: microbiomics, 201903–202202 collab research 3y $20m + research funding for microbiomics to support I-O therapies |
2019-03-11 |
| Snipr Biome–Life Sciences Partners: investment, 201903 financing round Series A totalling $50m incl co-lead investor LSP |
2019-03-11 |
| Snipr Biome–Lundbeck: investment, 201903 financing round Series A totalling $50m incl existing + co-lead investor Lundbeckfonden Emerge |
2019-03-11 |
| Snipr Biome–North-East Family Office: investment, 201903 financing round Series A totalling $50m incl co-investor North-East Family Office |
2019-03-11 |
| Snipr Biome–SEVERAL: investment, 201903 financing round Series A $50m co-led by Lundbeckfonden Emerge + Life Sciences Partners |
2019-03-11 |
| Snipr Biome–Wellington Partners: investment, 201903 financing round Series A totalling $50m incl co-investor Wellington Partners |
2019-03-11 |
| Qiagen–Tecan: lab automation, 201903– collab direct supply of Tecan Fluent workstation for sample to labs using QuantiFeron-TB Gold Plus test |
2019-03-08 |
| Gilde Investment–SEVERAL: investment, 201903 final close €200m Gilde Healthcare Service III fund incl PGGM/PF Zorg en Welzijn + Rabo Corp Investments |
2019-03-07 |
| SOM Biotech–SEVERAL: investment, 201903 financing round €7m led by European family holding |
2019-03-07 |
| BPCE–SEVERAL: investment, 201903 first closing €na of Seventure Health for Life Capital II Fund with final target size of over €200m |
2019-03-05 |
| Novasep–Sartorius: chromatography, 201903– collab developm of systems for membrane chromatography SSB |
2019-03-05 |
| abcr GmbH–Enzymicals: enzymes, 201903– collab distribution expansion ww sale of all catalogue products of Enzymcials by acbr |
2019-03-04 |
| Ascendis Pharma–SEVERAL: investment, 201903– public offering $400m+$60m ADSs |
2019-03-04 |
| Nightstar Therapeutics–Biogen: investment, 201903– acquisition $877m in cash at $25.5/share ANNOUNCED |
2019-03-04 |
| NovaGo Therapeutics–Neurimmune: investment, 201903 financing round Series A totalling CHF10m incl co-lead investor + strategic partner Neurimmune |
2019-03-04 |
| NovaGo Therapeutics–Pureos Bioventures: investment, 201903 financing round Series A totalling CHF10m incl co-lead investor Pureos Bioventures |
2019-03-04 |
| NovaGo Therapeutics–SEVERAL: investment, 201903 financing round Series A CHF10m co-led by Pureos Bioventures + Neurimmune |
2019-03-04 |
| Anaeropharma Science–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| CEPI–CureVac: mRNA vaccine production technology, 201903–202202 collab up to $34m developm of mobile mRNA printing facility |
2019-03-01 |
| Humedics–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| MycoTechnology–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| TargEDys–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| iOnctura–Optimum Strategic Communications: public relations, 201902 service existent by Optimum |
2019-02-28 |
| JnJ–AdoRx: adenosine receptor antagonists, 201902– collab developm + excl option €na lung cancer drugs with JnJ Innovation |
2019-02-28 |
| Sarepta Therapeutics–Centogene: molecular diagnostics, 201902–202002 collab service identifying DMD patients in MENA region by Centogene |
2019-02-28 |
| CN Innovations–MIT: organ-on-a-chip technology, 201902– license excl for organ-on-a-chip with human tissues fomr up to 10 organs for CN Bio |
2019-02-27 |
| Genfit–SEVERAL: investment, 201902–201903 private placement €9m with 500k ordinary shares at €18/share in Europe + outside North America |
2019-02-27 |
| Genfit–SEVERAL: investment, 201902–201903 US IPO $125m with 6.15m ADSs at $20.32/ADS at Nasdaq Global Select Market |
2019-02-27 |
| MeiraGTx–683 Capital Management: investment, 201902 private placement totalling $80m incl co-investor 683 Capital Management |
2019-02-27 |
| MeiraGTx–JnJ: investment, 201902 private placement totalling $80m incl $40m from lead investor JJDC Inc |
2019-02-27 |
| MeiraGTx–Orbimed: investment, 201902 private placement totalling $80m incl co-investor Orbimed Advisors |
2019-02-27 |
| MeiraGTx–Perceptive Advisors: investment, 201902 private placement totalling $80m incl co-investor Perceptive Advisors |
2019-02-27 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo-2011.jpg){kind=logo}
Date![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px](/banner/iito-20181119-600-060-lsus-life-sciences-usa-com-beta.jpg)
![Picture [iito] LSUS iitoLifeScience Transatlantic Life Sciences 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
